# Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients

> **NCT00553618** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Louisville** · enrollment: 160 (estimated)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Proleukin and Dacarbazine

## Key facts

- **NCT ID:** NCT00553618
- **Lead sponsor:** University of Louisville
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2007-08
- **Primary completion:** 2025-08
- **Final completion:** 2026-08
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2021-10-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00553618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00553618, "Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00553618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*